Gemma Salvadó

Aug 21, 2024 | nationalgeographic.es | Gemma Salvadó

Poder diagnosticar el Alzheimer con un análisis de sangre cambiaría las reglas del juego. Un nuevo análisis de sangre es capaz de diagnosticar el Alzheimer en adultos con una precisión del 90%, un diagnóstico que de otro modo requeriría analizar el líquido cefalorraquídeo o un escáner cerebral PET. Fotografía de Florentin Catargiu, 500px, Getty ImagesDemostrar que alguien tiene Alzheimer es actualmente un proceso caro e invasivo.

Jul 28, 2024 | jamanetwork.com | Shorena Janelidze |Gemma Salvadó |Suzanne Schindler |Sebastian Palmqvist

Key PointsQuestion  Which plasma biomarkers are useful to predict future development of Alzheimer disease (AD)–related β-amyloid (Aβ) pathology in cognitively unimpaired individuals (CU) with low brain Aβ levels?

Jun 13, 2024 | medrxiv.org | Rik Ossenkoppele |Gemma Salvadó |Shorena Janelidze |Alexa Pichet Binette

R.O. has received research support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics. He has given lectures in symposia sponsored by GE Healthcare and serves on advisory boards for Asceneuron and Bristol Myers Squibb. SP has acquired research support (for the institution) from ki elements / ADDF and Avid. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Biogen, Esai, Lilly, and Roche.

Mar 1, 2024 | nature.com | Joseph Therriault |Suzanne Schindler |Gemma Salvadó |Thomas K. Karikari |Melissa Murray |Inge M.W. Verberk | +5 more

AbstractDisease staging, whereby the spatial extent and load of brain pathology are used to estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard neuropathological diagnosis of AD. Current in vivo diagnostic frameworks for AD are based on abnormal concentrations of amyloid-β and tau in the cerebrospinal fluid or on PET scans, and breakthroughs in molecular imaging have opened up the possibility of in vivo staging of AD.